» Articles » PMID: 35528990

Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling

Overview
Specialty Gastroenterology
Date 2022 May 9
PMID 35528990
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Hepatocellular carcinoma (HCC) is listed as one of the most common causes of cancer-related death. Oncolytic therapy has become a promising treatment because of novel immunotherapies and gene editing technology, but biosafety concerns remain the biggest limitation for clinical application. We studied the the antitumor activity and biosafety of the wild-type Newcastle disease virus HK84 strain (NDV/HK84) and 10 other NDV strains.

Methods: Cell proliferation and apoptosis were determined by cell counting Kit-8 and fluorescein isothiocyanate Annexin V apoptosis assays. Colony formation, wound healing, and a xenograft mouse model were used to evaluate and oncolytic effectiveness. The safety of NDV/HK84 was tested in nude mice by an luciferase imaging system. The replication kinetics of NDV/HK84 in normal tissues and tumors were evaluated by infectious-dose assays in eggs. RNA sequencing analysis was performed to explore NDV/HK84 activity and was validated by quantitative real-time PCR.

Results: The cell counting Kit-8 assays of viability found that the oncolytic activity of the NDV strains differed with the multiplicity of infection (MOI). At an MOI of 20, the oncolytic activity of all NDV strains except the DK/JX/21358/08 strain was >80%. The oncolytic activities of the NDV/HK84 and DK/JX/8224/04 strains were >80% at both MOI=20 and MOI=2. Only NDV/HK84 had >80% oncolytic activities at both MOI=20 and MOI=2. We chose NDV/HK84 as the candidate virus to test the oncolytic effect of NDV in HCC in the and experiments. NDV/HK84 killed human SK-HEP-1 HCC cells without affecting healthy cells.

Conclusions: Intratumor infection with NDV/HK84 strains compared with vehicle controls or positive controls indicated that NDV/HK84 strain specifically inhibited HCC without affecting healthy mice. High-throughput RNA sequencing showed that the oncolytic activity of NDV/HK84 was dependent on the activation of type I interferon signaling.

Citing Articles

Oncolytic Virus Senecavirus A Inhibits Hepatocellular Carcinoma Proliferation and Growth by Inducing Cell Cycle Arrest and Apoptosis.

Gong T, Liu X, Li Q, Branch D, Loriamini M, Wen W J Clin Transl Hepatol. 2024; 12(8):713-725.

PMID: 39130624 PMC: 11310753. DOI: 10.14218/JCTH.2024.00125.


The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus.

Pathak U, Pal R, Malik N Life (Basel). 2023; 13(8).

PMID: 37629483 PMC: 10455894. DOI: 10.3390/life13081626.


Current advances in microbial-based cancer therapies.

Shahbaz A, Mahmood T, Javed M, Abbasi B Med Oncol. 2023; 40(7):207.

PMID: 37330997 DOI: 10.1007/s12032-023-02074-x.


A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy.

Bahreyni A, Liu H, Mohamud Y, Xue Y, Fan Y, Zhang Y BMC Med. 2023; 21(1):193.

PMID: 37226233 PMC: 10210435. DOI: 10.1186/s12916-023-02901-y.


Recent advances in oncolytic virus therapy for hepatocellular carcinoma.

Zhu L, Lei Y, Huang J, An Y, Ren Y, Chen L Front Oncol. 2023; 13:1172292.

PMID: 37182136 PMC: 10169724. DOI: 10.3389/fonc.2023.1172292.


References
1.
Altomonte J, Marozin S, Schmid R, Ebert O . Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther. 2009; 18(2):275-84. PMC: 2839313. DOI: 10.1038/mt.2009.231. View

2.
Hastie E, Grdzelishvili V . Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol. 2012; 93(Pt 12):2529-2545. PMC: 4091291. DOI: 10.1099/vir.0.046672-0. View

3.
Hallen L, Burki Y, Ebeling M, Broger C, Siegrist F, Oroszlan-Szovik K . Antiproliferative activity of the human IFN-alpha-inducible protein IFI44. J Interferon Cytokine Res. 2007; 27(8):675-80. DOI: 10.1089/jir.2007.0021. View

4.
Schirrmacher V . Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!. Biomedicines. 2017; 4(3). PMC: 5344264. DOI: 10.3390/biomedicines4030016. View

5.
Tayeb S, Zakay-Rones Z, Panet A . Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virother. 2016; 4:49-62. PMC: 4918379. DOI: 10.2147/OV.S78600. View